Q3 2025 Financial Performance - SkyWater achieved record Q3 2025 revenues of $150.7 million, exceeding the high end of the guidance range by over $9 million[7] - GAAP gross profit reached $36.2 million with a gross margin of 240%[125] - Adjusted EBITDA was $25.8 million, significantly surpassing forecasts[128] - Net income was $144 million, representing 95.5% of total revenue[128] Q4 2025 Guidance - The company expects Q4 2025 total revenues to be in the range of $155 million to $165 million[55] - SkyWater Texas revenue is projected to be between $84 million and $88 million[55] - Tools revenue is expected to be $17 million to $18 million, with a revised full-year expectation of $23 million to $24 million[55] - Adjusted EBITDA is guided to be in the range of $16 million to $22 million, with an adjusted EBITDA margin between 12.2% and 16.8%[146] Business Highlights and Growth Drivers - SkyWater anticipates strong growth in quantum computing customer revenues, expecting to exceed 30% in 2025[12] - The acquisition of Fab 25 in Texas has led to higher-than-expected revenue and profitability, with SkyWater now operating as two distinct reportable segments[12] - Advanced Packaging revenues are starting to ramp in Florida, with tool installations scheduled for completion in early 2026[12] - The company's acquisition added approximately 400,000 wafer/year capacity to the 200mm U S foundry supply base[29]

Pipeline and Clinical Development - Vopimetostat, a PRMT5 inhibitor, is in dose expansion for MTAP-del cancers and dose escalation for RAS-mut pancreatic and lung cancer, including combinations with RAS inhibitors[13] - TNG456, a brain-penetrant PRMT5 inhibitor, is in dose escalation for MTAP-del glioblastoma[13] - TNG961, an HBS1L degrader, has Phase 1 enabled for MTAP/FOCAD-del solid tumors[13] - A pivotal study for vopimetostat monotherapy in 2L MTAP-del pancreatic cancer is planned to start in 2026[23, 37] - Early data from the vopimetostat + RAS(ON) inhibitor clinical study is encouraging, with 30 patients dosed and both combinations well-tolerated[45, 48] Vopimetostat Clinical Data - Vopimetostat monotherapy demonstrated an Overall Response Rate (ORR) of 27% across 16 different histologies and a Disease Control Rate (DCR) of 78%[30] - In 2L pancreatic cancer, vopimetostat showed a median Progression-Free Survival (mPFS) of 7.2 months, more than twice historical Standard of Care (SOC) trials[32, 35] - In a histology-selective cohort, vopimetostat achieved an ORR of 49%, a DCR of 89%, and an mPFS of 9.1 months[50, 53] Financial Status - The company reported a cash balance of $343 million as of December 31, 2025, providing a cash runway into 2028[19, 81] Glioblastoma Focus - TNG456 is being developed for MTAP-del glioblastoma, which represents 45% of GBM cases, or approximately 7,000 patients per year in the US[23]

Pioneering CAR T in Autoimmune Diseases JP Morgan Healthcare Conference January 2026 Disclaimer and Forward-Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. ("Kyverna", "we", "our," or the "Company"). All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward looking statements inclu ...

Legend Biotech Corporate Presentation J.P. Morgan Healthcare Conference January 2026 © 2025 Legend Biotech. All rights reserved. Disclaimer This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established, except to the extent specifically provid ...

Corporate Presentation January 2026 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects ...

Delivering on the promise of Prime Editing Corporate Presentation January 2026 1 Forward Looking Statements This presentation contains forward-looking statements of Prime Medicine, Inc. ("Prime", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements contain information about our current and future prospects and our operations, which are based on currently available information. All statements other than statements of historica ...

Unmasking Advances in Oncology 44th Annual JP Morgan Healthcare Conference Dr. Sean McCarthy, CEO and Chairman January 14, 2026 © 2026 CytomX Therapeutics, Inc. 1 Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events, including those related to varsetatug masetecan and CX-801. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, techno ...

Business Overview - Concentra is the largest provider of occupational health services in the United States by number of locations[7] - The company cares for an average of over 52,000 patients each business day[7] - Concentra serves approximately 200,000 employer customers[7] - The company treats approximately 1 in every 4 injuries that occur within the U S workplace[12] - Concentra has over 1,000 total locations[12] Financial Performance - Concentra's TTM Revenue is $21 billion[8] - The company's TTM Adjusted EBITDA is $414 million[8] - Concentra's TTM Adjusted EBITDA margin is 198%[8] - The company's TTM free cash flow is $176 million[11] - Concentra's revenue from the largest employer customer is less than 3%[8]

Financial Performance and Growth - West Pharmaceutical Services achieved $2.9 billion in net sales in 2024[13] - The company anticipates a return to long-term organic growth of 7-9% with margin expansion[9, 55] - Adjusted operating margin was 19.8% in 2024[13] - Operating cash flow increased by 9% year-over-year in the first nine months of 2025[48] - Free cash flow increased significantly by 54% year-over-year in the first nine months of 2025[49] Market Trends and Opportunities - The injectables market is expected to grow from approximately $700 billion in 2024 to $1.2 trillion by 2030[15] - Biologics are anticipated to increase from 80% of the total injectables market value in 2024 to 90% in 2030[15] - GLP-1 elastomers represent 9% of revenue, and GLP-1 contract manufacturing represents 8% of revenue[26] - Commercialized Annex 1 opportunities are driving 200 bps of FY25 revenues[31] Product and Strategic Focus - High-value product (HVP) components constitute 48% of revenue and drive over 70% of gross profit[36, 37] - The company is selling manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie for $112.5 million, representing less than 4% of total company FY25 revenues[53]

Financial Performance & Outlook - Helios Technologies reported annual sales of $825 million[9] - The company's market capitalization stands at $2.1 billion[9] - Adjusted Free Cash Flow (FCF) conversion for TTM 3Q25 was 223%[38] - Net debt to TTM adjusted EBITDA ratio was 2.4x at the end of 3Q25, compared to 2.8x in the prior-year period[33] Segment Breakdown & Geography - Hydraulics segment accounts for 65% of the company's sales, while Electronics segment contributes 35%[10] - Americas represent 53% of the company's geographic sales, followed by APAC at 24% and EMEA at 23%[11] Capital Allocation & Debt Management - The company prioritizes debt repayment to provide future optionality on capital deployment[33] - Capital expenditures (CapEx) amounted to $6.7 million, representing 30% of sales in 3Q25[38] Strategic Initiatives - The company aims to shorten the cash conversion cycle through improved working capital management[40] - Helios celebrated its 55th anniversary in 2025[17]